Longwood Pharmaceuticals

Longwood Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for immunology, inflammation, and pain management. The company leverages its expertise in medicinal chemistry to target G-protein coupled receptors and ion channels with high specificity. Its lead candidate, LP-003, is a selective histamine H4 receptor antagonist currently undergoing clinical trials for conditions such as chronic spontaneous urticaria and atopic dermatitis. Operating with a global strategy, Longwood maintains research and development facilities in Beijing and clinical operations in the United States to address significant unmet medical needs in international markets.